#### 1 **Reversion of the inflammatory markers in patients with chronic limb** 2 threatening ischaemia 3 **Reversion of inflammation in CLTI** Joana Ferreira,<sup>1,2,3,4,5,\*</sup> Susana Roque,<sup>2,3</sup> Alexandre Lima Carneiro,<sup>6</sup> Adhemar Longatto-Filho<sup>2,3,7,8</sup> Isabel Vila,<sup>4,9,10</sup> Cristina Cunha,<sup>4,9,10</sup> Cristina Silva,<sup>4,9,10</sup> Amílcar Mesquita,<sup>11</sup> Jorge Cotter,<sup>2,3,4,9,10</sup> Margarida Correia-Neves,<sup>2,3</sup> Armando Mansilha,<sup>1,12,13</sup> Pedro Cunha,<sup>2,3,4,9,10</sup> 4 5 6 $\begin{array}{c} 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\end{array}$ <sup>1</sup> Vascular Surgery Department – Physiology and Surgery, Centro Hospitalar Universitário de São João, Porto, Portugal <sup>2</sup> Life and Health Science Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal <sup>b</sup> ICVS/3B's—PT Government Associated Laboratory, 4710-057 Braga, Portugal <sup>4</sup> Academic Center Hospital da Senhora da Oliveira, Guimarães, Portugal <sup>5</sup> Clinical Academic Center Hospital de Trás-os-Montes e Alto Douro—Professor Doutor Nuno Grande— CACTMAD, Vila Real, Portugal <sup>6</sup> Radiology Department - ULSAM, Viana do Castelo, Portugal <sup>7</sup> Department of Pathology (LIM-14), University of São Paulo School of Medicine, São Paulo, Brazil Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil <sup>9</sup> Medicine Department, Hospital da Senhora da Oliveira, Guimarães, Portugal <sup>10</sup> Center for the Research and Treatment of Arterial Hypertension and Cardiovascular Risk, Internal Medicine Department, Hospital da Senhora da Oliveira, Guimarães, Portugal <sup>11</sup> Vascular Surgery Department - Hospital da Senhora da Oliveira, Guimarães, Portugal <sup>12</sup> Department of Angiology and Vascular Surgery, Centro Hospitalar Universitário de São João, Porto, Portugal <sup>13</sup> Faculty of Medicine, University of Porto, Porto, Portugal 23 \* Joana Ferreira, Centro Hospitalar Universitário de São João, 4200-319, Porto, Portugal, joana222@gmail.com 24 ABSTRACT 25 Introduction: Peripheral arterial disease (PAD) affects over 202 million individuals worldwide, 26 with 1.3% suffering from chronic limb-threatening ischaemia (CLTI). Atherosclerosis, 27 characterized by intense inflammation, is the primary cause of PAD. Inflammation is linked to 28 higher mortality rates, especially in CLTI patients. This study aims to compare the evolution of 29 inflammatory markers between claudication and CLTI patients over three, six, and twelve 30 months.

31 Methods: A prospective, single-center observational study was conducted from January 2018 to 32 July 2022. A PAD cohort was observed at admission and at three, six, and twelve months, with 33 data on clinical, analytical, and inflammatory markers collected. The analyzed markers included 34 positive acute phase proteins (C-reactive protein - CRP and fibrinogen) and negative acute 35 phase proteins (albumin, total cholesterol, and high-density lipoprotein - HDL).

36 **Results:** The study involved 119 subjects (mean age:  $67.58 \pm 9.60$  years; 79.80% males), with 37 65 patients having claudication and 54 with CLTI. At admission, CLTI patients exhibited 38 significantly higher serum levels of CRP and fibrinogen (positive acute phase proteins) and 39 lower levels of albumin, total cholesterol, and HDL (negative acute phase proteins) compared to 40 claudication patients. Three months after CLTI resolution, negative acute phase proteins 41 increased, and positive acute phase proteins decreased. However, no significant changes in 42 inflammatory proteins were observed in patients with claudication over time.

43 Conclusion: CLTI patients demonstrate an inflammatory state, which may have deleterious
 44 consequences and be partially reversible after the resolution of the ischemic process.
 45 Recognizing the potential for reversibility through revascularization/amputation underscores the
 46 significance of timely intervention.

47 Keywords: atherosclerosis, peripheral arterial disease, critical limb ischaemia, inflammation

48 1. INTRODUCTION

49 Lower extremity peripheral arterial disease (PAD) is characterized by atherosclerosis occurring 50 in the lower limbs and affects over 230 million adults worldwide[1,2]. Due to its high 51 prevalence in low and middle-income countries PAD is becoming an increasingly global 52 problem. The most advanced stage of PAD is chronic limb threatening ischemia (CLTI) which 53 accounts for 11% of diagnosed PAD cases[1]. Patients with CLTI have a worse prognosis, with 54 at least 20% of them dying within one year of diagnosis[3].

55 PAD and inflammation are particularly connected. Inflammation plays a significant role in the 56 initiation and progression of atherosclerosis, particularly in PAD[4,5]. Traditional 57 cardiovascular risk factor exerts their proatherogenic role, at least in part, through an 58 inflammatory mechanism[4,6]. Also important is to acknowledge the important role of 59 inflammation on the acceleration of the systemic arteriosclerotic process, leading equally to 60 terminal cardiovascular and renal disease [7,8]. Pro-inflammatory cytokines [interleukin-6 (IL-6) 61 and tumor-necrosis factor-a (TNFa), TNF soluble receptor-II (TNFaSRII)] are strongly linked 62 to PAD[6]. The lower limbs, which possess a large vascular bed, frequently harbor inflamed 63 plaques that release inflammatory mediators. These mediators contribute to the development of 64 coronary artery disease, thereby explaining the higher incidence of coronary artery disease in 65 PAD patients[4]. The prevalence of coronary artery disease in PAD ranges from 43% to 90%, 66 while the prevalence of PAD in coronary artery disease patients is less than 25%[4]. Studies 67 have shown that the severity of coronary atherosclerosis is related with the degree of 68 inflammatory response in the affected PAD limb[4]. Consequently, it has been suggested that it 69 is not PAD itself, but rather its systemic inflammatory activity, that is associated with an 70 increased number of coronary events[4].

71 The main aim of this study is to determine the evolution of the inflammatory parameters at 72 three, six and twelve months in patients with claudication and with CLTI.

The second objective is to assess the differences in inflammatory parameters between patientswith claudication and those with CLTI, through time.

### 75 **2. METHODS**

76 2.1 Study Type, Inclusion/Exclusion Criteria, Ethical Considerations

An observational, prospective, study was conducted from January 2018 to July 2020 at a single institution. Consecutive patients with PAD, attending the Vascular Surgery consultations or admitted at the Vascular Surgery ward who fulfilled the required criteria were included. Inclusion criteria: Patients with PAD suggested by the clinical history and objective examination and, confirmed with ankle-brachial index (ABI). Exclusion Criteria: Any disease responsible for body composition changes or pro-inflammatory state in the last three months.

Ethics approval was obtained from the local Hospital, with the protocol number 75/2017. All
the participants signed the informed consent.

85 2.2. Clinical Characteristics

Patient's age, gender, PAD clinical stage (CLTI and claudication), arterial hypertension, diabetes, dyslipidemia, smoking habits and medication were collected at admission and defined as previously stated [9]. Fontaine stage III was defined as persistent rest pain for more than two weeks [10]. Fontaine stage IV was defined as ischemic skin lesions [10]. Both cases were confirmed with the following hemodynamic parameters: ankle pressure below 50mmHg, or absent palpable ankle pulses or toe pressure below 30mmHg in patients with diabetes and incompressible vessels [11].

93 The patients were schedule for an evaluation at three, six and twelve months. The clinical 94 evolution, amputation rate (major and minor), death and causes of death were registered.

### 95 2.3. Inflammatory Parameter

96 The serum inflammatory parameters determined were positive acute phase proteins (C-reactive

97 Protein- CRP- and fibrinogen) and negative acute phase proteins (albumin, total cholesterol and

98 high-density lipoprotein- HDL).

Blood Samples were collected after a 10–12 hours fast in the morning, taken into appropriate Vacutainer, centrifuged within 5min for 4000 cycle/minute, and serum was separated. The serum inflammatory parameters were evaluated at admission, three, six and twelve months of follow up, and tests were performed by routine procedures in the department of clinical

103 chemistry.

### 104 2.4. Statistical Analysis

105 Continuous variables were expressed as the mean  $\pm$  standard deviation (SD) and as the 106 percentage for categorical variables. The Shapiro-Wilk test was used to assess all continuous 107 variables for normality. Between-group differences in continuous variables were assessed with 108 Student's t-test or with the Mann-Whitney U test, and the effect size r was determined by 109 calculating the ratio between test statistics Z and the square root of the number of pairs n. 110 Categorical variables between two groups were compared with Chi-square. Wilcoxon Signed 111 Rank test and paired samples t-test were used to study the evolution of acute phase proteins and 112 analytic data, comparing 4 time points (t = admission; t = 3 months, t = 6 months and t = 12

- 113 months).
- 114 A p-value of less than .05 was considered significant. Statistical evaluation was performed using
- 115 SPSS software, version 20.0 (SPSS, Inc., Chicago, IL, USA).

### 116 **3. RESULTS**

117 3.1. Clinical Characteristics at Admission

118 A total 119 patients (95 men) with an average age of  $67.58 \pm 9.60$  years-old with PAD were 119 enrolled in the study. The group of patients was evenly distributed as 65 patients (54.62%) had 120 claudication and 54 (45.38%) had CLTI. Nineteen of these patients had rest pain.

121 No differences were registered between patients with claudication and CLTI on age, gender,

122 cardiovascular risk factors and medication, except on smoking habits (Table I). There was a

123 significant higher prevalence of smokers and a higher smoking load in claudication group

- 124 [Claudication: Median = 40.00; IQR = 45.00; CLTI: Median = 13.00; IQR = 40.00; p = 0.031]
- 125 (Table 1).
- 126 Tab. 1 Cardiovascular risk factor and comorbidities of the PAD population
- 127 *3.2. Clinical Evolution*

128 During the follow-up, 28 (23.53%) patients had completed four clinical visits and reached the 129 end of the follow-up; 52 (43.70%) patients had three appointments and 93 (78.15%) two. Out of 130 the 65 patients with claudication, 14 (21.54%) improved their symptoms with medical therapy, 131 five (7.69%) had worsening symptoms and one patient was readmitted due to CLTI. Six 132 (5.04%) deaths were registered: five in patients with CLTI, one in a patient with claudication. 133 The causes of death were: acute myocardial infarction (3 patients); heart failure (2 patients); 134 pulmonary infection (1 patients); lung cancer (1 patient). Thirty patients (55.56%) with CLTI 135 were submitted to minor amputation [23 (42.59%) and 12 (22.22%) to major amputations].

- 136 3.3. Inflammatory Parameters
- At admission patients with CLTI had significantly higher serum levels of positive acute phase proteins (CRP, and fibrinogen) and lower serum level of negative acute phase proteins (albumin, total cholesterol and HDL), when compared to patients with claudication (Table 2).
- Tab. 1 Positive (CRP and fibrinogen) and negative (HDL, albumin and total cholesterol) acute phase proteins determined in PAD patients, at admission.
- 142 No differences were found in patients with CLTI, between Fontaine stage III and IV on the 143 serum level of acute phase proteins (Table 3).
- 144**Tab. 3** Evolution of negative acute phase proteins (HDL, albumin and total cholesterol) and positive acute phase145proteins (CRP and fibrinogen) in patients with CLTI at three, six and twelve months
- 146 *3.4. Evolution of Inflammatory Parameters*

- 147 Analyzing the evolution of acute phase proteins patients, we noted that three months after the
- resolution of the ischemic process in patients with CLTI (by amputation or revascularization)
- there was an increase in serum levels of HDL and albumin (negative acute phase proteins) and
- decrease in CRP and fibrinogen (positive acute phase proteins (Table 4). These differences were
- 151 not registered at six or twelve months (Table 4). No differences were noted through time in 152 patients with claudication (Table 5)
- **Tab. 4** Evolution of negative acute phase proteins (HDL and albumin) and positive acute phase proteins (CRP and fibrinogen) in patients with CLTI at three, six and twelve months
- 155 **Tab. 5** Evolution of inflammatory markers in patients with claudication through the time points analysed.
- 156 We also noted that for most inflammatory markers the difference between those who had
- 157 claudication and patients with CLTI was present at three months but disappeared at six and
- 158 twelve months. (Fig. 1)
- 159 Fig. 1 Comparison of acute phase proteins between patients with claudication and with CLTI at three, six and twelve months.

### 161 **4. DISCUSSION**

162 To the best of our knowledge, this paper is one of the first reporting the possibility of partially 163 reversing the inflammatory state in patients with CLTI, after resolution of the critical limb 164 ischemia event. The novelty of this study lies in the observation that three months following the 165 resolution of the ischemic process, there is a reversal of the inflammatory markers, and the 166 differences between CLTI and claudicants disappear at six months. To our knowledge, no other 167 study has compared the inflammatory markers between CLTI and claudicants over such an 168 extended period of time.

#### 169 4.1. Inflammatory Parameters in CLTI and Patients with Claudication

We observed that patients with CLTI have a significant higher level in CRP and fibrinogen (positive acute phase proteins) and a significant lower serum level of albumin, total cholesterol and HDL (negative acute phase proteins) compared to patients with claudication, as we have previously demonstrated [9].

174 We hypothesized that this inflammatory pattern could be caused by the extension of 175 atherosclerosis lesions, tissue infection or the ischemic tissue process. It has been reported that 176 the severe reduction in tissue oxygenation present in patients with CLTI, can trigger an 177 inflammatory reaction, leading to an increase in fibrinogen levels [12]. The elevated fibrinogen 178 levels result in higher blood viscosity, promoting thrombosis, and potentially explaining the 179 higher risk of graft occlusion, stroke, myocardial infarction or death observed in CLTI patients 180 [3,12]. Increased plasma viscosity also impairs the vessel perfusion, particularly in small vessels 181 such as capillaries, increasing tissue ischemia [13].

182 The inflammatory reaction also contributes to the generation of a proatherogenic lipid profile 183 characterized by low HDL, oxidized LDL and high triglycerides [14]. We observed that the 184 CLTI patients had low HDL and high triglyceride levels. Additionally, patients with CLTI had a 185 lower albumin level which are considered a powerful predictor of mortality [14].

To investigate whether the inflammation in CLTI patients is primarily caused by tissue infection, we compared the serum levels of acute phase proteins between patients in Fontaine stage III and stage IV, but no differences were found, as suggested by other authors [13].

- 189 Our hypothesis was that the differences in inflammatory markers between CLTI and claudicants
- 190 could be explained by the activity and extension of the atherosclerotic process in patients with
- 191 critical limb ischemia. However, the pattern of evolution of the inflammatory markers (that we
- discuss below) suggests that it is the ischemic tissue process, rather than the extension of
- 193 atherosclerotic plaques, that causes the differences between CLTI and claudicants.
- 194 4.2. Evolution of Inflammatory Parameters
- 195 We observed that three months after the resolution of the CLTI state (by amputation or surgery),
- 196 there was a reversion, at least in part, of the inflammatory parameters, with an increase in the

197 negative acute phase proteins (HDL and albumin) and a decrease in positive acute phase 198 proteins (CRP and fibrinogen). These differences were not observed in patients with 199 claudication or at other periods of time in patients with CLTI. At three months, patients with 200 CLTI maintained a higher serum level of CRP and fibrinogen and lower levels of albumin 201 compared to patients with claudication. However, these differences disappeared at six months. 202 Our findings align with two previous studies: Bismuth et al. reported a decrease in CRP and an 203 increase in HDL, and albumin after revascularization in 30 patients with CLTI [15]. Woodburn 204 et al. compared fibrinogen levels in 56 patients with CLTI at admission and 16 weeks after 205 revascularization, observing a reduction in fibrinogen levels, although they remained higher 206 than those of the controls [3]. The normalization of fibrinogen levels following successful 207 vascular surgery of critically ischemic limbs (revascularization or amputation) suggests that 208 tissue ischemia may stimulate hepatic fibrinogen synthesis, possibly through interleukin-6 209 produced by activated monocytes [12]. Both of these studies analyzed the data at three months, 210 and no other study has examined the data over a longer follow-up period.

211 4.3. Clinical Implications

212 Demonstrating that following the resolution of CLTI that there is a decrease in serum levels of 213 inflammatory markers suggests that the deleterious impact of inflammation can be mitigated 214 with a prompt intervention.

215 This study also highlights the potential role of anti-inflammatory medical therapy in PAD 216 patients. For example, cankinumab is an interleukin-1 $\beta$  inhibitor that improved walking 217 performance in patients with claudication while reducing blood CRP and IL-6 [16]. Statins have 218 been associated with a reduction in systemic inflammation, as measured by CRP, and have 219 shown benefits in terms of lower mortality, reduced major adverse cardiovascular and 220 cerebrovascular events, and longer amputation-free survival in CLI patients [6,16,17]. The 221 benefit of statins are closely related to their anti-inflammatory effect [18]. Fibrates also exhibit 222 fibrinogen-lowering action[6].

### 223 4.4. Strengths and Limitations

224 Strengths of the paper:

- Comprehensive investigation: The paper explores the association between PAD and inflammation, and the evolution of inflammatory parameters in patients with claudication and those with CLTI over a period of three, six, and twelve months.
- 228
   2. Comparison between claudication and CLTI patients over an extended period of time: The study compares patients with claudication and CLTI in terms of their inflammatory parameters. By examining the differences between these two groups, the researchers can better understand the impact of disease severity on inflammation.
- 3. Findings on the reversal of inflammatory state in CLTI patients: The study reports that three months after the resolution of the ischemic process, there is a partial reversal of the inflammatory state in CLTI patients. This finding suggests that prompt intervention and anti-inflammatory therapies may help alleviate the detrimental effects of inflammation in PAD patients.
- 237
  4. Comparing the Stage III and IV of Fontaine Classification: The paper reports no difference in the serum levels of acute phase proteins between patients on stage III and IV. This fact underlines the role of the ischemic tissue in the inflammatory changes registered in patients with CLTI.
- 241 This research work as several limitations:
- Sample size: The study included a total of 119 patients, followed by the main author
   which may not be representative of the entire PAD population followed at our
   institution. A larger sample size could provide more robust and generalizable results.
- 2452. Prevalence of men in the studied population: Approximately 80% of the recruited246 sample were men. As such the results cannot be generalized to all population.
- Short follow-up period (even if the longest recorded in the literature): The study
   evaluated the evolution of inflammatory parameters at three, six, and twelve months.

#### However, a longer follow-up period could provide more insights into the long-term changes and trends in inflammatory markers. However, as far as we know this is the longest follow-up published.

- 4. Single-center study: The study was conducted at a single institution, which may limit
  the generalizability of the findings. A multi-center study could provide a more
  comprehensive understanding of the topic.
- 2555. Other factors: The paper did not investigate other potential factors that could influence256 the inflammatory state, as the genetic, the practice of exercise or dietary habits.
- Causality: This research work is also not able to establish any a causal relationship
  between the resolution of the ischemia process and the improve in the inflammatory
  data.

### 260 **5.** CONCLUSIONS

This study provides valuable insights into the evolution of inflammatory parameters in patients with PAD, specifically comparing those with CLTI to claudicants. It emphasizes that patients with CLTI exhibits an inflammatory state that can be at least partially reverted after the resolution of the ischemic process, thereby mitigating the negative impact of inflammation.

### 265 FUNDING

266 This work was supported by the Portuguese Society of Vascular Surgery.

267 This work was developed under the scope of project NORTE-01-0145-FEDER- 000013,

supported by the Northern Portugal Regional Operational Programme (NORTE 2020) under the

269 Portugal Partnership Agreement, through the European Regional Development Fund (FEDER),

and by National funds, through the Foundation for Science and Technology (FCT) - project

271 UIDB/50026/2020 and UIDP/50026/2020.

# 272 CONFLITS OF INTEREST STATEMENT

273 The authors have no conflicts of interest to declare.

## 274 AUTHOR'S CONTRIBUTIONS

275 Joana Ferreira – Conceived of the presented idea; wrote the manuscript, collected and analysed 276 the data. Susana Roque - Determined the serum level of inflammatory markers, conceived the 277 methods relating to the laboratory measurements of myokines, revised the manuscript. 278 Alexandre Lima Carneiro - Helped in the manuscript writing, in the data analysis and made the 279 statistical analysis. Adhemar Longatto-Filho- Analyzed the data and revised the manuscript. 280 Isabel Vila – Collected the clinical data, helped in the manuscript writing and revised the paper. 281 Cristina Cunha - Collected the clinical data, helped in the manuscript writing and revised the 282 paper. Cristina Silva - Collected the clinical data, helped in the manuscript writing and revised 283 the paper. Amílcar Mesquita – Revised the paper and contributed to the final manuscript. Jorge 284 Cotter - Revised the paper and contributed to the final manuscript. Margarida Correia-Neves -285 Revised the paper and contributed to the final manuscript. Armando Mansilha – Supervise the 286 paper, revised the paper and contributed to the final manuscript. Pedro Cunha - Contributed to 287 the design, collected the data, revised the paper and contributed to the final manuscript.

### 288 **REFERENCES**

289 [1] Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, McDermott MM, 290 Misra S, Ujueta F; American Heart Association Council on Epidemiology and Prevention; 291 Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular 292 Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on 293 Peripheral Vascular Disease; and Stroke Council. Lower Extremity Peripheral Artery Disease: 294 Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement 295 From the American Heart Association. Circulation. 2021 Aug 31;144(9):e171-e191. doi: 296 10.1161/CIR.0000000000001005. Epub 2021 Jul 28. Erratum in: Circulation. 2021 Aug 297 31;144(9):e193. PMID: 34315230; PMCID: PMC9847212.

[2] Signorelli SS, Fiore V, Malaponte G. Inflammation and peripheral arterial disease: the value of circulating biomarkers (Review). Int J Mol Med. 2014 Apr;33(4):777-83. doi: 10.3892/ijmm.2014.1657. Epub 2014 Feb 13. PMID: 24535646.

301 [3] Woodburn KR, Rumley A, Lowe GD, Pollock JG. Fibrinogen and markers of fibrinolysis
302 and endothelial damage following resolution of critical limb ischaemia. Eur J Vasc Endovasc
303 Surg. 1995 Oct;10(3):272-8. doi: 10.1016/s1078-5884(05)80042-5. PMID: 7552524.

304 [4] Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease.
305 Circulation. 2010 Nov 2;122(18):1862-75. doi: 10.1161/CIRCULATIONAHA.109.918417.
306 PMID: 21041698.

[5] Cauley JA, Kassem AM, Lane NE, Thorson S; Osteoporotic Fractures in Men (MrOS) Study
Research Group. Prevalent peripheral arterial disease and inflammatory burden. BMC Geriatr.
2016 Dec 9;16(1):213. doi: 10.1186/s12877-016-0389-9. PMID: 27938334; PMCID:
PMC5148838.

[6] Doweik L, Maca T, Schillinger M, Budinsky A, Sabeti S, Minar E. Fibrinogen predicts
mortality in high risk patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2003
Oct;26(4):381-6. doi: 10.1016/s1078-5884(03)00340-x. PMID: 14511999.

314 [7] Zanoli L, Briet M, Empana JP, Cunha PG, Mäki-Petäjä KM, Protogerou AD, Tedgui A, 315 Touvz RM, Schiffrin EL, Spronck B, Bouchard P, Vlachopoulos C, Bruno RM, Boutouvrie P; 316 Association for Research into Arterial Structure, Physiology (ARTERY) Society, the European 317 Society of Hypertension (ESH) Working Group on Vascular Structure and Function, and the 318 European Network for Noninvasive Investigation of Large Arteries. Vascular consequences of 319 inflammation: a position statement from the ESH Working Group on Vascular Structure and 320 Function and the ARTERY Society. J Hypertens. 2020 Sep;38(9):1682-1698. doi: 321 10.1097/HJH.00000000002508. PMID: 32649623; PMCID: PMC7610698.

[8] Laurent S, Boutouyrie P, Cunha PG, Lacolley P, Nilsson PM. Concept of Extremes in
Vascular Aging. Hypertension. 2019 Aug;74(2):218-228. doi:
10.1161/HYPERTENSIONAHA.119.12655. Epub 2019 Jun 17. PMID: 31203728.

[9] Ferreira J, Carneiro A, Vila I, Silva C, Cunha C, Longatto-Filho A, Mesquita A, Cotter J,
Mansilha A, Correia-Neves M, Cunha P. Inflammation and Loss of Skeletal Muscle Mass in
Chronic Limb Threatening Ischemia. Ann Vasc Surg. 2023 Jan;88:164-173. doi:
10.1016/j.avsg.2022.07.009. Epub 2022 Aug 2. PMID: 35926785.

[10] Novo S, Coppola G, Milio G. Critical limb ischemia: definition and natural history. Curr
Drug Targets Cardiovasc Haematol Disord. 2004 Sep;4(3):219-25. doi:
10.2174/1568006043335989. PMID: 15379613.

[11] Gerassimidis T, Karkos CD, Karamanos D, Kamparoudis A. Current endovascular
management of the ischaemic diabetic foot. Hippokratia. 2008 Apr;12(2):67-73. PMID:
18923656; PMCID: PMC2464305.

[12] Pedrinelli R, Dell' Omo G, Barchielli A, Berchiolli R, Melillo E, Mariani M, Balbarini A,
Ferrari M. Fibrinogen and mortality in chronic critical limb ischaemia. J Intern Med. 1999
Jan;245(1):75-81. doi: 10.1046/j.1365-2796.1999.00410.x. PMID: 10095820.

- Rudofsky G, Strubel G, Michler E, Kuegler C, Biro F. Influence of fibrinogen and hematocrit on the early outcome of angioplasty in patients with PAOD. J Endovasc Ther. 2004
  Apr;11(2):125-31. doi: 10.1583/01-651R.1. PMID: 15056033.
- [14] Kaysen GA. Biochemistry and biomarkers of inflamed patients: why look, what to assess.
  Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S56-63. doi: 10.2215/CJN.03090509. PMID: 19996007.
- 344 [15] Bismuth J, Kofoed SC, Jensen AS, Sethi A, Sillesen H. Serum lipids act as inverse acute
  345 phase reactants and are falsely low in patients with critical limb ischemia. J Vasc Surg. 2002
  346 Nov;36(5):1005-10. doi: 10.1067/mva.2002.128301. PMID: 12422112.
- [16] Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of
  Peripheral Artery Disease. Circ Res. 2021 Jun 11;128(12):1868-1884. doi:
  10.1161/CIRCRESAHA.121.318258. Epub 2021 Jun 10. PMID: 34110910.
- [17] Gary T, Belaj K, Hafner F, Eller P, Rief P, Hackl G, Brodmann M. Graz Critical Limb
  Ischemia Score: A Risk Score for Critical Limb Ischemia in Peripheral Arterial Occlusive
  Disease. Medicine (Baltimore). 2015 Jul;94(27):e1054. doi: 10.1097/MD.00000000001054.
  PMID: 26166076; PMCID: PMC4504640.
- [18] Paquissi FC. The role of inflammation in cardiovascular diseases: the predictive value of
  neutrophil-lymphocyte ratio as a marker in peripheral arterial disease. Ther Clin Risk Manag.
  2016 May 27;12:851-60. doi: 10.2147/TCRM.S107635. PMID: 27313459; PMCID:
- 357 PMC4892833.

Tab. 1 - Cardiovascular risk factor and comorbidities of the PAD population

|                                | Claudication (n=65) | CLTI (n=54) | X <sup>2</sup> | df | <i>p</i> -value | Phi     |
|--------------------------------|---------------------|-------------|----------------|----|-----------------|---------|
| Male (n; %)                    | 55; 84.61           | 40; 74.07   | 1.555          | 1  | 0.212           | 0.115   |
| Hypertension (n; %)            | 49; 75.38           | 37; 68.52   | 0.694          | 1  | 0.405           | 0.076   |
| Dyslipidemia (n; %)            | 41; 63.08           | 32; 59.26   | 0.181          | 1  | 0.670           | 0.039   |
| Smoker/ex-smoker (n; %)        | 53; 81.53           | 30; 55.56   | 7.969          | 1  | 0.005*          | 0.261   |
| Diabetes (n; %)                | 23; 35.38           | 28; 51.85   | 3.266          | 1  | 0.071           | - 0.166 |
| Coronary artery disease (n; %) | 9; 13.85            | 6; 11.11    | 0.200          | 1  | 0.654           | 0.041   |
| Statins (n;%)                  | 58; 89.23           | 44; 81.48   | 0.961          | 1  | 0.327           | 0.090   |
| Fibrate (n;%)                  | 4; 6.15             | 5; 9.26     | Fisher         | -  | 0.512           | 0.063   |
| Ezetimibe (n;%)                | 3; 4.615            | 3; 5.55     | Fisher         | -  | 0.812           | 0.022   |
| Antiplatelet (n;%)             | 54; 83.08           | 40; 74.07   | 1.042          | 1  | 0.307           | 0.094   |
| ACEi/ARA (n;%)                 | 20; 30.77           | 16; 29.63   | 0.000          | 1  | 0.989           | 0.001   |
| Beta-blockers (n;%)            | 13; 20.00           | 11; 20.37   | 0.003          | 1  | 0.953           | 0.005   |

Note: Application of Chi-Square test and Fisher's exact test.

ACEi: angiotensin-converting enzyme inhibitors.

ARA: angiotensin receptor antagonists

CLTI: chronic limb-threatening ischemia

|                           | Claudication (n=65) |           | CLTI (n=54) |        | U  | <i>p</i> -value                                  | r         |
|---------------------------|---------------------|-----------|-------------|--------|--|--|-----------|
|                           | Median              | IQR       | Median      | IQR    |  |  |           |
| CRP (g/dL)                | 2.90                | 2.15      | 6.80        |        | 900.00                                   | 0.000*   | - 0.383   |
| Fibrinogen (mg/dL)        | 293.00              | 88.00     | 415.50      | 298.75 | 1162.50                                  | 0.000*   | - 0.375   |
| HDL (mg/dL)               | 50.00               | 16.00     | 37.00       |        | 652.50                                   | 0.000*   | 0.462     |
| Albumin (g/dL)            | 4.00                | 0.35      | 3.60        |        | 997.50                                   | 0.003*   | 0.281     |
|                           | Claudicati          | on (n=65) | CLTI (r     | i=54)  | Levene's F test; p                       | <i>p</i> -value                                  | Cohen's d |
| Total cholesterol (mg/dL) | 161.79 :            | ± 34.43   | 146.42 ±    | 38.27  | <i>F</i> (104) = 0.033; <i>p</i> = 0.856 | <i>t</i> (104) =2.176; <i>p</i> = <b>0.034</b> * | 0.422     |

Tab. 2 - Positive (CRP and fibrinogen) and negative (HDL, albumin and total cholesterol) acute phase proteins determined in PAD patients, at admission

Note: Application of Mann-Whitney U test. CRP and fibrinogen do not have a normal distribution, determined with Shapiro-Wilk test (p < 0.05).

**CLTI:** chronic limb-threatening ischemia

CRP: c-reactive protein

|                           | IV (n=35) |         | III (n=19) |        | U                        | <i>p</i> -value                 | r         |
|---------------------------|-----------|---------|------------|--------|--------------------------|---------------------------------|-----------|
|                           | Median    | IQR     | Median     | IQR    |                          |                                 |           |
| CRP (g/dL)                | 38.15     | 64.15   | 10.71      | 4.40   | 287.00                   | 0.714                           | - 0.050   |
| Fibrinogen (mg/dL)        | 491.69    | 297.50  | 327.58     | 120.00 | 187.50                   | 0.373                           | - 0.121   |
| HDL (mg/dL)               | 38.90     | 18.00   | 50.07      | 20.00  | 232.00                   | 0.730                           | - 0.047   |
| Albumin (g/dL)            | 3.39      | 0.85    | 4.05       | 0.60   | 190.50                   | 0.051                           | - 0.269   |
|                           | IV (n     | =35)    | III (n=    | =19)   | Levene's F test; p       | <i>p</i> -value                 | Cohen's d |
| Total cholesterol (mg/dL) | 143.52    | ± 36.78 | 152.80 ±   | 41.97  | F(46) = 1.198; p = 0.280 | t(46) =- 0.776; <i>p</i> =0.442 | 0.235     |

Tab. 3 - Positive (CRP and fibrinogen) and negative (HDL, albumin and total cholesterol) acute phase proteins determined in patients with CLTI (Fontaine III vs Fontaine IV), at admission

Note: Application of Mann-Whitney U test. CRP and fibrinogen do not have a normal distribution, determined with Shapiro-Wilk test (p < 0.05).

CLTI: chronic limb-threatening ischemia

CRP: c-reactive protein

| Tab. 4 - Evolution of negative acute phase proteins (HDL, albumin and total cholesterol) and positive acute phase proteins (CRP and fibrinogen) in |
|--|
| patients with CLTI at three, six and twelve months   |

|                  | HDL (mg/DL) |       | Albumin (g/dL) |     | Total cholesterol (mg/dL) |       | CRP (g/DL) |     | Fibrinogen (mg/dL) |        |
|------------------|-------------|-------|----------------|-----|---------------------------|-------|------------|-----|--------------------|--------|
|                  | Median      | IQR   | Median         | IQR |                           | p     | Median     | IQR | Median             | IQR    |
| Admission (n=54) | 37.00*      | 15.00 | 3.60**         | -   | 146.42 ± 38.27            |       | 6.80*      | -   | 398.00**           | 303.75 |
| 3 months (n= 32) | 45.00*      | 17.50 | 3.70**         | -   | 154.80 ± 46.36            | 0.352 | 2.90*      | -   | 370.28**           | 181.00 |
| 6 months (n= 13) | 44.00       | -     | 4.50           | -   | 156.81 ± 52.51            | 0.563 | 4.90       | -   | 298.00             | 125.00 |
| 12 months (n=3)  | 44.00       | -     | 4.30           | -   | 152.33 ± 67.72            | 0.634 | 3.90       | -   | 292.00             | 84.59  |

**Note:** \*p = 0.026 (p = 0.674; p = 0.180) \*\* p = 0.000 (p = 0.114; p = 0.109); \*p = 0.038 (p = 0.374; p = 0.655) \*\* p=0.036 (p = 0.929; p = 0.180) **CRP:** C-Reactive Protein

|                  | HDL (mg/DL) |       | Albumir | Albumin (g/dL) |        | g/DL) | Fibrinogen (mg/dL) |        |
|------------------|-------------|-------|---------|----------------|--------|-------|--------------------|--------|
|                  | Median      | IQR   | Median  | IQR            | Median | IQR   | Median             | IQR    |
| Admission (n=65) | 50.00       | 16.00 | 4.00    | 0.35           | 2.90   | 2.15  | 293.00             | 88.00  |
| 3 months (n=61)  | 53.00       | 19.00 | 3.90    | 0.32           | 3.10   | 2.33  | 311.00             | 90.00  |
| 6 months (n=39)  | 53.00       | 54.00 | 3.95    | 0.33           | 3.70   | 6.33  | 295.00             | 143.00 |
| 12 months (n=25) | 49.00       | 17.00 | 4.10    | 0.73           | 2.90   | 1.42  | 294.00             | 96.50  |

Tab. 5 - Evolution of negative acute phase proteins (HDL and albumin) and positive acute phase proteins (CRP and fibrinogen) in patients with claudication at three, six and twelve months

Note: Application of Friedman test. HDL and albumin do not have a normal distribution, determined with Shapiro-Wilk test (\*< 0.05).

CRP: c-reactive protein

